Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00464178 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 2 study, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00464178 is a Phase 2 study that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 7 participants.
The verdict
NCT00464178, a Phase 2 study, was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination of bevacizumab and bortezomib have increased efficacy in the treatment of relapsed/ refractory multiple myeloma.
Interventions
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00464178
The ClinicalTrials.gov registry entry for NCT00464178 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bortezomib is the first listed.
NCT00464178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00464178 about?
NCT00464178 is a clinical study titled "A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma". The purpose of this study is to determine whether the combination of bevacizumab and bortezomib have increased efficacy in the treatment of relapsed/ refractory multiple myeloma.
What is the current status of trial NCT00464178?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2007-04. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00464178?
The interventions under investigation include: Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00464178?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.